We found that the inhibition of CDK7 decreased the binding of MED1 across the LIMD1-AS1 super-enhancer, but not the promoter, in LN-18 and T98G glioma cells (Fig. 6P–S). This evidence concerns the gene MED1 and central nervous system cancer.